These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 12447161)

  • 1. Cost-effectiveness of beta-blocker treatment in heart failure.
    Gilbert EM
    Rev Cardiovasc Med; 2002; 3 Suppl 3():S42-7. PubMed ID: 12447161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost effectiveness of beta blocker therapy for patients with chronic severe heart failure in Ireland.
    Barry M
    Ir Med J; 2002 Jun; 95(6):174, 176-7. PubMed ID: 12171265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Economic analysis of the treatment of heart failure with beta-blockers].
    Díez-Manglano J
    Med Clin (Barc); 2013 Sep; 141(6):265-70. PubMed ID: 23597957
    [No Abstract]   [Full Text] [Related]  

  • 4. Multinational economic evaluation of valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT).
    Reed SD; Friedman JY; Velazquez EJ; Gnanasakthy A; Califf RM; Schulman KA
    Am Heart J; 2004 Jul; 148(1):122-8. PubMed ID: 15215801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis of bisoprolol treatment for heart failure.
    Di Stasi F; Scalone L; De Portu S; Menditto E; Mantovani LG
    Ital Heart J; 2005 Dec; 6(12):950-5. PubMed ID: 16502708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic implications of extended-release metoprolol succinate for heart failure in the MERIT-HF trial: a US perspective of the MERIT-HF trial.
    Caro JJ; Migliaccio-Walle K; O'Brien JA; Nova W; Kim J; Hauch O; Hillson E; Wedel H; Hjalmarson A; Gottlieb S; Deedwania PC; Wikstrand J;
    J Card Fail; 2005 Dec; 11(9):647-56. PubMed ID: 16360958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. From cost of illness to cost-effectiveness in heart failure.
    Lévy E
    Eur Heart J; 1998 Dec; 19 Suppl P():P2-4. PubMed ID: 9886705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Will beta-blockers save money?
    Heidenreich PA
    J Card Fail; 2005 Dec; 11(9):657-8. PubMed ID: 16360959
    [No Abstract]   [Full Text] [Related]  

  • 9. New studies influencing treatment of heart failure: 2006 update.
    Dunlap ME
    Pharmacotherapy; 2007 Apr; 27(4 Pt 2):3S-11S. PubMed ID: 17381369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Cost-effectiveness of bisoprolol in chronic heart failure].
    Ekman M; Zethraeus N; Dahlström U; Höglund C
    Lakartidningen; 2002 Feb; 99(7):646-50. PubMed ID: 11887711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost effectiveness of carvedilol for heart failure.
    Delea TE; Vera-Llonch M; Richner RE; Fowler MB; Oster G
    Am J Cardiol; 1999 Mar; 83(6):890-6. PubMed ID: 10190405
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Bisprolol in heart failure: efficacy and costs in a French setting according to CIBIS II].
    Lévy P; Mérot JL; Lechat P; Lévy E; Bogillot O
    Therapie; 2001; 56(4):421-5. PubMed ID: 11677866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carvedilol reduces the costs of medical care in severe heart failure: an economic analysis of the COPERNICUS study applied to the United Kingdom.
    Stewart S; McMurray JJ; Hebborn A; Coats AJ; Packer M;
    Int J Cardiol; 2005 Apr; 100(1):143-9. PubMed ID: 15820297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness results from the US Carvedilol Heart Failure Trials Program.
    Vera-Llonch M; Menzin J; Richner RE; Oster G
    Ann Pharmacother; 2001; 35(7-8):846-51. PubMed ID: 11485131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic implications of treatment guidelines for congestive heart failure.
    Shibata MC; Nilsson C; Hervas-Malo M; Jacobs P; Tsuyuki RT
    Can J Cardiol; 2005 Dec; 21(14):1301-6. PubMed ID: 16341301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug copayment and adherence in chronic heart failure: effect on cost and outcomes.
    Cole JA; Norman H; Weatherby LB; Walker AM
    Pharmacotherapy; 2006 Aug; 26(8):1157-64. PubMed ID: 16863491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survival and hospitalization in heart failure patients with or without diabetes treated with beta-blockers.
    Bobbio M; Ferrua S; Opasich C; Porcu M; Lucci D; Scherillo M; Tavazzi L; Maggioni AP;
    J Card Fail; 2003 Jun; 9(3):192-202. PubMed ID: 12815569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nebivolol: a third-generation beta-blocker for hypertension.
    Cheng JW
    Clin Ther; 2009 Mar; 31(3):447-62. PubMed ID: 19393838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Are beta-blockers as efficacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic heart failure? A meta-analysis of large-scale clinical trials.
    Haas SJ; Vos T; Gilbert RE; Krum H
    Am Heart J; 2003 Nov; 146(5):848-53. PubMed ID: 14597934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF): rationale and design.
    Fonarow GC; Abraham WT; Albert NM; Gattis WA; Gheorghiade M; Greenberg B; O'Connor CM; Yancy CW; Young J
    Am Heart J; 2004 Jul; 148(1):43-51. PubMed ID: 15215791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.